Sanofi reports an historic step for the potential first US OTC switch of an erectile dysfunction drug while refusing even the slightest nod toward an imminent spin-out of its consumer business, a key driver in its 8.6% net sales growth for its latest quarter.
Sanofi Starting US Cialis OTC Actual Use Study Soon While Tamiflu Switch Progress Delayed
French Pharma Reports €1.33Bn Q1 Consumer Health Sales Helped By Price Increases
After 118.2% cough/cold sales growth leads 17% overall consumer business growth, Sanofi points to still stronger days ahead while keeping the business under the same roof with its pharmaceutical and vaccine divisions.
More from Deals
• By
By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.
• By
Direct seller has deals to fully acquire and 51% ownership of Link BioSciences, which formulates personalized supplements. It also announced a deal to acquire Pruvit Ventures, ketone supplements direct seller.
• By
Australia's SFI Health looking to take Equazen omega-3 fatty acids supplement to new markets to capitalize on Europe's fast-growing brain health segment.
• By
A journey began eight years ago continues for Doc Generici – now rebranded as DOC Pharma – as it continues to diversify its offerings beyond conventional generic prescription pharmaceuticals.
More from Business
• By
Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.
• By
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
• By
Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.